Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)14.66
  • Today's Change0.08 / 0.55%
  • Shares traded60.55m
  • 1 Year change-67.60%
  • Beta1.3496
Data delayed at least 15 minutes, as of May 10 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 09-May-24
Select bar for recommendation details.
Recommendations09-May-24
Buy10
Outperform9
Hold10
Underperform0
Sell0

Share price forecast in CNY

The 23 analysts offering 12 month price targets for WuXi Biologics (Cayman) Inc have a median target of 20.99, with a high estimate of 61.95 and a low estimate of 11.99. The median estimate represents a 43.15% increase from the last price of 14.66.
High322.6%61.95
Med43.1%20.99
Low-18.2%11.99

Earnings history & estimates in CNY

WuXi Biologics (Cayman) Inc reported annual 2023 earnings of 1.06 per share on Mar 26, 2024.
Average growth rate+40.68%
More ▼

Revenue history & estimates in CNY

of 10.29bn. This equaled the revenue expectation of the one analyst following the company. The same period last year the company did not report revenues.
WuXi Biologics (Cayman) Inc. had revenues for the full year 2023 of 17.03bn. This was 11.56% above the prior year's results.
Average growth rate+46.04%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.